Leap Therapeutics announces orphan drug designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer

This article was originally published here

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. “Orphan Drug Designation for DKN-01

The post Leap Therapeutics announces orphan drug designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply